PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): From molecular mechanism to human AML

Carcinogenesis

Volumn 36, Issue 4, 2014, Pages 413-419

  Verbiest, Tom ^a,b   Bouffler, Simon ^a   L Nutt, Stephen ^c,d   Badie, Christophe ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR PU 1; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; TP53 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; CHROMOSOME 2; CHROMOSOME ABERRATION; DOWN REGULATION; EXON; EXPERIMENTAL MODEL; GENE; HEMATOPOIETIC CELL; HUMAN; MOLECULAR MECHANICS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SFPI1 GENE; TARGET CELL; X RAY; ACUTE MYELOBLASTIC LEUKEMIA; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GAMMA RADIATION; GENE DELETION; GENE TRANSLOCATION; GENETICS; LEUKEMIA; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FMS-LIKE TYROSINE KINASE 3; GAMMA RAYS; GENE DELETION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, RADIATION-INDUCED; MICE; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 84927672510     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv016     Document Type: Review

References (66)

1. Upton, A.C. (1986) Historical perspectives on radiation carcinogenesis. In Upton,A.C., Albert,R.E., Burns,F.J. and Shore,R.E. (eds) Radiation Carcinogenesis. Elsevier, New York, pp. 1-10.
2. Hsu, W.L. et al. (2013) The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat. Res., 179, 361-382.
3. Major, I.R. (1979) Induction of myeloid leukaemia by whole-body single exposure of CBA male mice to x-rays. Br. J. Cancer, 40, 903-913.
4. Rithidech, K.N. et al. (1999) Advantages of the CBA mouse in leukemogenesis research. Blood Cells Mol. Dis., 25, 38-45.
5. Bouffler, S.D. et al. (1997) Chromosome 2 hypersensitivity and clonal development in murine radiation acute myeloid leukaemia. Int. J. Radiat. Biol., 72, 181-189.
6. Darakhshan, F. et al. (2006) Evidence for complex multigenic inheritance of radiation AML susceptibility in mice revealed using a surrogate phenotypic assay. Carcinogenesis, 27, 311-318.
7. Rithidech, K.N. et al. (1993) A specific chromosomal deletion in murine leukemic cells induced by radiation with different qualities. Exp. Hematol., 21, 427-431.
8. Bouffler, S.D. et al. (1996) Chromosomal abnormalities in neutroninduced acute myeloid leukemias in CBA/H mice. Radiat. Res., 146, 349-352.
9. Hirouchi, T. et al. (2008) Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice. Exp. Hematol., 36, 871-885.
10. Steffen, L.S. et al. (2013) Molecular characterisation of murine acute myeloid leukaemia induced by 56Fe ion and 137Cs gamma ray irradiation. Mutagenesis, 28, 71-79.
11. Alexander, B.J. et al. (1995) Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia. Leukemia, 9, 2009-2015.
12. Silver, A. et al. (1999) Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12. Genes Chromosomes Cancer, 24, 95-104.
13. Peng, Y. et al. (2009) Radiation leukemogenesis in mice: loss of PU.1 on chromosome 2 in CBA and C57BL/6 mice after irradiation with 1 GeV/nucleon 56Fe ions, X rays or gamma rays. Part I. Experimental observations. Radiat. Res., 171, 474-483.
14. Cleary, H. et al. (2001) Allelic loss on chromosome 4 (Lyr2/TLSR5) is associated with myeloid, B-lympho-myeloid, and lymphoid (B and T) mouse radiation-induced leukemias. Blood, 98, 1549-1554.
15. Finnon, R. et al. (2012) Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia. Leukemia, 26, 1445-1446.
16. Cook, W.D. et al. (2004) PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood, 104, 3437-3444.
17. Jawad, M. et al. (2006) Evidence for clustered tumour suppressor gene loci on mouse chromosomes 2 and 4 in radiation-induced acute myeloid leukaemia. Int. J. Radiat. Biol., 82, 383-391.
18. Suraweera, N. et al. (2005) Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene, 24, 3678-3683.
19. Welch, J.S. et al. (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell, 150, 264-278.
20. Cancer Genome Atlas Research Network. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059-2074.
21. Genik, P.C. et al. (2014) Leukemogenesis in heterozygous PU.1 knockout mice. Radiat. Res., 182, 310-315.
22. Metcalf, D. et al. (2006) Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A., 103, 1486-1491.
23. Dekkers, F. et al. (2011) A two-mutation model of radiation-induced acute myeloid leukemia using historical mouse data. Radiat. Environ. Biophys., 50, 37-45.
24. Brown, N.L. et al. (2011) Sfpi1/PU.1 mutations in mouse radiationinduced acute myeloid leukaemias affect mRNA and protein abundance and associate with disrupted transcription. Leuk. Res., 35, 126-132.
25. Mohrin, M. et al. (2010) Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell, 7, 174-185.
26. Ban, N. et al. (2009) Implication of replicative stress-related stem cell ageing in radiation-induced murine leukaemia. Br. J. Cancer, 101, 363-371.
27. Shao, L. et al. (2014) Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a-and Arf-independent manner. Blood, 123, 3105-3115.
28. Hirouchi, T. et al. (2011) Cell surface marker phenotypes and gene expression profiles of murine radiation-induced acute myeloid leukemia stem cells are similar to those of common myeloid progenitors. Radiat. Res., 176, 311-322.
29. Staber, P.B. et al. (2013) Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol. Cell, 49, 934-946.
30. Nutt, S.L. et al. (2005) Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J. Exp. Med., 201, 221-231.
31. Olme, C.H. et al. (2013) Live cell detection of chromosome 2 deletion and Sfpi1/PU1 loss in radiation-induced mouse acute myeloid leukaemia. Leuk. Res., 37, 1374-1382.
32. Olme, C.H. et al. (2013) Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells. Mutat. Res., 756, 119-126.
33. Dahl, R. et al. (2003) Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat. Immunol., 4, 1029-1036.
34. Kueh, H.Y. et al. (2013) Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science, 341, 670-673.
35. Chen, H. et al. (1995) PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene, 11, 1549-1560.
36. Okuno, Y. et al. (2005) Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol. Cell. Biol., 25, 2832-2845.
37. Rosenbauer, F. et al. (2004) Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat. Genet., 36, 624-630.
38. Bonadies, N. et al. (2010) PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element. Oncogene, 29, 1062-1072.
39. Scott, E.W. et al. (1994) Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science, 265, 1573-1577.
40. Scott, E.W. et al. (1997) PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity, 6, 437-447.
41. McKercher, S.R. et al. (1996) Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J., 15, 5647-5658.
42. Kamath, M.B. et al. (2008) Dose-dependent repression of T-cell and natural killer cell genes by PU.1 enforces myeloid and B-cell identity. Leukemia, 22, 1214-1225.
43. Dakic, A. et al. (2005) PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J. Exp. Med., 201, 1487-1502.
44. Iwasaki, H. et al. (2005) Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood, 106, 1590-1600.
45. Heinz, S. et al. (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell, 38, 576-589.
46. Ghisletti, S. et al. (2010) Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity, 32, 317-328.
47. Dakic, A. et al. (2007) Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol., 28, 108-114.
48. Turkistany, S.A. et al. (2011) The transcription factor PU.1 is a critical regulator of cellular communication in the immune system. Arch. Immunol. Ther. Exp. (Warsz)., 59, 431-440.
49. Carotta, S. et al. (2010) The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dosedependent manner. Immunity, 32, 628-641.
50. Basova, P. et al. (2014) Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene, 33, 4735-4745.
51. Moreau-Gachelin, F. et al. (1988) Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature, 331, 277-280.
52. Kayser, S. et al. (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood, 117, 2137-2145.
53. Pedersen-Bjergaard, J. et al. (2008) Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia, 22, 240-248.
54. Nakanishi, M. et al. (1999) Chromosomal instability in acute myelocytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors. J. Radiat. Res., 40, 159-167.
55. Mueller, B.U. et al. (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood, 100, 998-1007.
56. Bonadies, N. et al. (2010) Heterozygous deletion of the PU.1 locus in human AML. Blood, 115, 331-334.
57. Steidl, U. et al. (2006) Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat. Genet., 38, 1269-1277.
58. Durual, S. et al. (2007) Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia, 21, 1050-1059.
59. Mueller, B.U. et al. (2006) ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood, 107, 3330-3338.
60. Corces-Zimmerman, M.R. et al. (2014) Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia, 28, 2276-2282.
61. Vangala, R.K. et al. (2003) The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood, 101, 270-277.
62. Staber, P.B. et al. (2014) The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. Blood, 124, 2391-2399.
63. Walter, M.J. et al. (2005) Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc. Natl. Acad. Sci. U. S. A., 102, 12513-12518.
64. Mizuki, M. et al. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164-3173.
65. O'Connell, R.M. et al. (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med., 205, 585-594.
66. Curik, N. et al. (2012) 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia, 26, 1804-1811.